TB Patients' COVID-19 vaccine response under the microscope

NCT ID NCT05571735

Recruiting now Knowledge-focused Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares the immune response to COVID-19 vaccines between people being treated for tuberculosis (TB) and healthy individuals. About 133 participants in the Thailand-Myanmar border area will receive one of three vaccines (Pfizer, AstraZeneca, or Janssen). Researchers will measure antibody and cell-based immunity over one year to see if TB treatment affects vaccine effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: COVID-19 vaccines (Pfizer-BioNTech, AstraZeneca, or Janssen)
What this could lead to: If successful, this could show that TB patients mount a similar immune response to COVID-19 vaccines as healthy people, helping guide vaccination policies for this group.
What could go wrong: This is a small observational study, not a large trial. Results may not apply to all TB patients or other settings, and immune response does not guarantee protection from COVID-19.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 PANDEMICS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 PANDEMICS TUBERCULOSIS

Contacts and locations

Locations

Shoklo Malaria Research Unit (SMRU)
RECRUITING

Mae Ramat, Changwat Tak, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.